ACIâ„¢-OR Program Schedule
Friday, October 3, 2014
8:00 am - 3:30 pm
Amphitheater
Earle A. Chiles Research Institute, Providence Cancer Center
4805 NE Glisan Street
Portland, OR 97213
Program Schedule
Presentations included allotted time for Audience Response System (ARS) assisted audience
interaction as well as general question and answer time.
| 7:00 am - 8:00 am | Registration |
| 7:00 am - 8:00 am | Continental Breakfast |
| 8:00 am - 8:10 am | Welcome and Overview Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
| Session I: Basic Principles of Tumor Immunology and Immunotherapy 2.25 AMA PRA Category 1 Credits™ |
|
| 8:10 am - 9:05 am | Immunology 101  Amy E. Moran, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 9:05 am - 9:35 am | Regulation of the Immune Response Michael J. Gough, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 9:35 am - 10:05 am | Principles of Immunotherapy Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 10:05 am - 10:20 am | Panel Discussion |
| 10:20 am - 10:35 am | Break |
| Session II: Checkpoint Blockade-Based Immunotherapy 2.25 AMA PRA Category 1 Credits™ |
|
| 10:35 am - 11:05 am | CTLA-4 Blockade: Indications and Clinical Management Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 11:05 am - 11:35 am | Blockade of the PD-1/PDL-1 Axis Inhibition Omid Hamid, MD - The Angeles Clinic and Research Institute |
| 11:35 am - 12:05 pm | Combinations and Other Immune Checkpoint Inhibitors/Agonists Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 12:05 pm - 12:25 pm | Radiation and Immunotherapy Marka R. Crittenden, MD, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 12:25 pm - 12:45 pm | Panel Discussion |
| 12:45 pm - 1:30 pm | Lunch |
| Session III: Non-Checkpoint Blockade-Based Immunotherapy 2 AMA PRA Category 1 Credits™ |
|
| 1:30 pm - 2:00 pm | Cytokines (IL-2 and IFN): Indications and Clinical Management Brendan D. Curti, MD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 2:00 pm - 2:30 pm | Adoptive T Cell Therapy with Variations Mark Faries, MD –The John Wayne Cancer Institute |
| 2:30 pm - 3:00 pm | Vaccines Keith S. Bahjat, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
| 3:00 pm - 3:20 pm | Panel Discussion |
| 3:20 pm - 3:30 pm | Closing Remarks Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute, Providence Cancer Center |
